Impact of the Use of Nandrolone on the Treatment of Malnutrition Induced by Cancer

Impact of the Use of Nandrolone on the Treatment of Malnutrition Induced by Cancer

Compare the use of nandrolone associated with corticosteroid for the treatment of cancer-induced malnutrition to treatment with corticosteroids alone in patients with tumors in the high gastro-intestinal tract, liver, pancreas and bile ducts in palliative treatment.

• Compare muscle mass values obtained before and after the use of anabolic steroids upon assessment by bioelectrical impedance analysis (BIA).
• Compare the anabolic effect on quality of life (QLo) of the patient before and after the use of anabolic steroids.
• Compare data from laboratory tests such as complete blood count, albumin, C reactive protein and transferrin with drug intervention.

Inclusion Criteria:

• Cancer patients above 18 years old.
• Patients with tumors in the high gastro-intestinal, hepatobiliary and pancreatic tracts in palliation.
• Patients able to undergo BIA.
• Malnourished patients as per the subjective global assessment produced by the patient (ASG-PPP) and whose score is greater than nine.
• Patients who agree to participate in the study.

Exclusion Criteria:

• Patients with malignant tumors of other metachronous or synchronous location except nonmelanoma skin tumor
• Patients with chronic renal failure.
• Patients on diuretics, recent or chronic.
• Patients on appetite stimulants and anabolic agents.
• Patients using pacemakers, which can interfere with the results of BIA